New Evidence, Guidelines Support Mavacamten Use in Hypertrop

A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.

Related Keywords

United States , China , Amy Sehnert , Pablo Garc , Milind Desai , European Society Of Cardiology , Bristol Myers Squibb , European Union , Heart Failure Clinical Development , European Society , Bristol Myers , Inherited Cardiac Diseases , Heart Failure Unit , Septal Reduction , Eur Heart , Mavacamten , Camzyos , Phcm , Johcm , Hypertrophic Cardiomyopathy ,